A new nasal spray with the potential to fight COVID-19 and other respiratory viral infections will be tested in the hopes of manufacturing it in Australia, reports New Daily.
The INNA-051 nasal treatment, developed by Australian biotech company Ena Respiratory, targets the primary site of most respiratory infections, including COVID-19. Applied topically with a spray, the treatment activates the immune defence mechanisms in the respiratory tract.
The technology could also help fight coronavirus and other infections like influenza and the common cold.
The federal government announced that along with a private partner it would provide $11.7 million to fund the testing, as part of the Biomedical Translation Fund. If tests are successful, the product will be manufactured in Australia.
Full New Daily report
MedicalBrief Archives: Preventive nasal spray cuts viral replication in half in Australian animal study